50
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CSF biomarker changes precede symptom onset of mild cognitive impairment.

      Neurology
      Aged, Amyloid beta-Peptides, cerebrospinal fluid, Biological Markers, Disease Progression, Female, Humans, Male, Middle Aged, Mild Cognitive Impairment, Neuropsychological Tests, Peptide Fragments, Proportional Hazards Models, Survival Analysis, tau Proteins

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study evaluated longitudinal CSF biomarker measures collected when participants were cognitively normal to determine the magnitude and time course of biomarker changes before the onset of clinical symptoms in subjects with mild cognitive impairment (MCI). Longitudinal CSF collection and cognitive assessments were performed on a cohort of 265 participants who were cognitively normal at their baseline assessment and subsequently developed MCI or dementia. CSF β-amyloid 1-42 (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) were determined longitudinally. Consensus diagnoses were completed annually. Cox regression analyses were performed, with baseline CSF values and time-dependent rate of change in CSF values as covariates (adjusted by baseline age, race, and education), in relation to time to onset of mild cognitive symptoms. The mean time from baseline to onset of mild cognitive symptoms was 5.41 years. Increased risk of progressing from normal cognition to onset of clinical symptoms was associated with baseline values of Aβ1-42, p-tau, and the ratios of p-tau/Aβ1-42 and t-tau/Aβ1-42 (p < 0.002). Additionally, the rate of change in the ratios of t-tau/Aβ1-42 (p < 0.004) and p-tau/Aβ1-42 (p < 0.02) was greater among participants who were subsequently diagnosed with MCI. Baseline differences in CSF values were predictive of clinical symptoms that were a harbinger of a diagnosis of MCI more than 5 years before symptom onset, and continue to show longitudinal changes as cognitive symptoms develop, demonstrating that baseline and longitudinal changes in CSF biomarkers are evident during the preclinical phase of Alzheimer disease.

          Related collections

          Author and article information

          Comments

          Comment on this article